Quilter 13F: Cuts Pfizer (PFE) Stake by $1.2M
Key Points
- Quilter lowered its position in Pfizer Inc. PFE by 6.2% during the quarter, dropping 41,417 shares to end with 621,511 shares valued at $17,725,493.
- Pfizer Inc. PFE recently traded around $30.11, sitting above both its 50-day and 200-day moving averages as it approaches its next earnings report on November 3, 2026.
- Major Wall Street firms including Guggenheim, HSBC, Scotiabank, Cantor Fitzgerald, and JP Morgan recently updated their outlooks on the healthcare giant.
Get Pfizer text alerts
We text you when insiders, Congress, analysts or big funds move on $PFE.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Pfizer Inc. alert may contain errors. Disclosures
Quilter reduced its stake in Pfizer Inc. PFE by 41,417 shares during the quarter, according to a Form 13F filing with the U.S. Securities and Exchange Commission on October 21, 2026. The stock closed at $29.85 on the day of the filing.
PFE
Pfizer Inc.
Quilter vs. the S&P 500
Hypothetical returns from Quilter's disclosed trades, not real profit or advice. How we model this.
What Changed in Quilter's Pfizer Position
Quilter trimmed its investment in the healthcare company by 6.2%, bringing its holdings down to 621,511 shares. The remaining stake carried a reported value of $17,725,493 at the time of the filing. In the prior quarter, the firm held 662,928 shares.
Other Institutional Activity in Pfizer
Other large money managers also adjusted their positions in the drug maker. Brandes Investment Partners grew its holdings by 478,043 shares, ending with 9,107,225 shares worth about $240,385,208. Fisher Asset Management, LLC lifted its stake by 4,104,062 shares to 109,067,291 shares valued at $3,255,658,677. Bank Of New York Mellon Corporation added 3,998,010 shares for a total holding of 57,879,546 shares worth $1,727,704,470.
Pfizer Inc. Stock Up 0.4%
Pfizer Inc. PFE recently traded around $30.11 as of October 22, 2026, up about 0.9% from its event-close price of $29.85. The share price sits roughly 7.0% above its 50-day moving average of $28.15 and about 13.0% above its 200-day moving average of $26.64. The stock trades near the top of its 52-week range, which runs from a low of $23.62 to a high of $30.25.
Recent Earnings
Pfizer generated $63.7 billion in trailing-twelve-month revenue with an EPS of $0.76. The company posted a net profit margin of 6.8% and a return on equity of 5.0%. The drug maker is scheduled to report its next set of financial results on November 3, 2026.
Dividend
Pfizer pays an annual dividend of $1.72 per share, which translates to a dividend yield of 5.76% based on recent trading levels. The payout ratio sits at 226.3%.
Insider Buying and Selling at Pfizer Inc.
Company insiders completed open-market transactions ahead of the filing period. Shantanu Narayen bought 2,059 shares on June 26, 2026, at $24.29 per share for a total of $50,013.11. Cyrus Taraporevala acquired 1,544 shares on the same day at $24.29 each, totaling $37,503.76. Joseph Echevarria picked up 1,904 shares at $24.29 for a total value of $46,248.16, while James Quincey purchased 1,595 shares at $24.29 for $38,742.55.
Analysts Set New Price Targets
Wall Street research firms maintain varied perspectives on the stock. On August 7, 2026, Guggenheim kept a Buy rating while lowering its price target to $31.00 from $35.00. HSBC maintained a Hold rating on September 10, 2026, raising its target to $30.00 from $28.00. Scotiabank kept a Sector Outperform rating on October 6, 2026, lifting its target to $33.00 from $30.00. Cantor Fitzgerald maintained a Neutral rating on October 8, 2026, raising its target to $28.00 from $27.00, and JP Morgan kept a Neutral rating on October 9, 2026, boosting its target to $30.00 from $28.00. The stock carries a consensus Buy recommendation and an average analyst target of $29.26 across 26 opinions.
About Pfizer
Headquartered in New York, Pfizer Inc. discovers, develops, and supplies biopharmaceutical products globally. It operates through segments focused on innovative biopharmaceuticals and commercial portfolios, supplying medicines and vaccines across multiple therapeutic areas.
Bottom Line
Investors will look toward Pfizer's upcoming earnings release on November 3, 2026, for further insight into revenue trends and operational margins. Institutional ownership shifts and evolving analyst targets will continue to shape market sentiment around the healthcare provider.
Related Filing Alerts
Source: Quilter's 13F filing on $PFE (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts